The fact
The biopharmaceutical company, focused on liver diseases, crosses a critical threshold at 14 euros.
Investors fear dilution or a major clinical failure.
Click the link to read an article on the topic:
The biopharmaceutical company, focused on liver diseases, crosses a critical threshold at 14 euros.
Investors fear dilution or a major clinical failure.